Reuters logo
BRIEF-MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis
December 19, 2016 / 11:28 AM / a year ago

BRIEF-MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis

Dec 19 (Reuters) - MediciNova Inc

* MediciNova announces phase 2b trial of MN-166 (ibudilast) in progressive MS will continue as planned following DSMB review of interim efficacy analysis

* Results of final data analysis from study are expected in second half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below